Among these developments is trastuzumab deruxtecan (brand name: Enhertu), which offers new hope specifically for patients who harbor HER2 mutations in their lung cancer, a type once challenging to ...

61.9% of patients with HER2-mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response. Breakthrough Therapy Designation recently granted in the US for ENHERTU in ...

Enhertu has a black box warning for harm it can cause to an unborn fetus and for a severe side effect called interstitial lung disease (ILD). This is the most serious type of warning given by the FDA.

Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.

Lung problems that may be severe, life-threatening or that may lead to death. ... Redefining Treatment for More Than 60 Percent of HER2-Negative Metastatic Breast Cancer Patients; ENHERTU ...

Enhertu, an engineered HER2-directed antibody-drug conjugate, is approved for several advanced or metastatic cancers, including HER2-positive breast cancer. Safety concerns for Enhertu include ...

Approval based on DESTINY-Lung02 trial results where Daiichi Sankyo and AstraZeneca’ s ENHERTU demonstrated a confirmed objective response rate of 49.0% and median duration of response of 16.8 ...

References: Enhertu® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease ...

AZ and Daiichi Sankyo have previously been awarded breakthrough designations for Enhertu as a treatment for second- and later-line therapy of HER2-positive breast cancer, as well as HER2-positive ...

Learn how CT scans, biopsies, and blood tests help detect lung cancer early, improving treatment outcomes and survival rates. Skip to main content . ... (Enhertu) and ado-trastuzumab emtansine ...